Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Abatacept, ATC L04AA24 für die Zeit 01.09.2026 - 31.08.2028

Section 130a (8) SGB V allows health insurance funds and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, a regular process of substance-related, formal tendering procedures takes place in accordance with the regulations of Part 4 of the GWB by the DAK-Gesundheit. For the pharmaceuticals to be specified by the bidder in Annex 2 to the contract for the above-mentioned substance Abatacept, ATC L04AA24, the DAK-Gesundheit intends to conclude pharmaceutical discount contracts with as many interested pharmaceutical companies as possible until the entry into force of new pharmaceutical discount contracts. A discount contract under the approval model for the above-mentioned substance comes into force for the first time on 01.09.2026 and expires on 31.08.2028. It ends automatically with the entry into force of the exclusive contract, regardless.